EXEL Exelixis Inc.

21.03
-0.26  -1%
Previous Close 21.29
Open 20.9
Price To Book 6.87
Market Cap 6287615329
Shares 298,983,135
Volume 3,382,824
Short Ratio
Av. Daily Volume 4,162,486

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiated 3Q 2017.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
Phase 3 trial initiation announced July 10, 2017.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 trial met primary endpoint - September 24, 2017. Japanese regulatory filing due 1Q 2018.
Esaxerenone (CS-3150)
Essential hypertension
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018. Approval announced December 19, 2017.
Cabozantinib - CABOSUN
First-Line RCC - cancer
PDUFA date January 14, 2019.
Cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer
Phase 3 trial initiation announced October 8, 2018.
Cabozantinib
Thyroid Carcinoma
Phase 1 presentation at ASCO 2018.
CABOMETYX (cabozantinib) + Nivolumab and Ipilimumab
Urothelial Carcinoma
Phase 3 trial has completed enrollment.
IMspire150 - cobimetinib, atezolizumab and vemurafenib
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
Phase 1b trial expansion announced June 1, 2018.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
Phase 3 initiation announced December 5, 2018.
CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)
Hepatocellular Carcinoma

Latest News

  1. 3 Biotechs Gilead Sciences Could Buy in March
  2. 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
  3. The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
  4. Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
  5. Report: Developing Opportunities within Exelixis, Cintas, BGC Partners, FirstEnergy, Hologic, and Trevena — Future Expectations, Projections Moving into 2018
  6. Do Hedge Funds Love Exelixis, Inc. (EXEL)?
  7. Here's Why Exelixis Stock Jumped 46.4% in November
  8. Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
  9. Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis
  10. Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma
  11. Why Exelixis (EXEL) Could Be Positioned for a Surge
  12. Why Clovis Oncology Stock Rose 48% in November
  13. See what the IHS Markit Score report has to say about Exelixis Inc.
  14. Why Exelixis Stock Soared 46% in November
  15. Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Exelixis
  16. Why Is Exelixis (EXEL) Up 35.9% Since Last Earnings Report?
  17. Biotech's Tackling Major Issues You Should Know
  18. Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss
  19. 3 Top Growth Stocks to Buy Right Now
  20. Is Exelixis Inc’s (NASDAQ:EXEL) CEO Being Overpaid?